TME Pharma N.V. AI Stock Analysis
Want to see FR:ALTME full AI Analyst Report?
TME Pharma N.V. (ALTME) AI Stock Analysis
TME Pharma N.V.
(Paris:ALTME)
The overall score is heavily pressured by the company's dire financial state, including insolvency and lack of revenue, which are the most significant risk factors. While the stock exhibits positive short-term technical momentum, this is a secondary factor that does not offset the fundamental risk of financial distress. The negative P/E ratio further confirms the lack of underlying value.
TME Pharma N.V. (ALTME) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 10.01M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.94M
- Price to Earnings (P/E)
- -5.8
- Beta (1Y)
- -0.73
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- France
- Employees
- 12
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
TME Pharma N.V. Business Overview & Revenue Model
Company Description
TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipelin...
How the Company Makes Money
Public, company-specific detail sufficient to describe TME Pharma N.V.’s revenue model and key revenue streams in a factual way is not available in the provided prompt context; therefore: null
TME Pharma N.V. Financial Statement Overview
Summary
Financial health is critically weak. The company has negligible revenue, consistent operating losses, negative equity of -$1.58M indicating insolvency, and deeply negative free cash flow. While the cash burn rate has improved, the business model is not viable without substantial new capital.
Income Statement
15Very NegativeBalance Sheet
2Very NegativeCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -27.00K | 0 | 19.00K | 17.00K | 0 | 33.00K |
| Gross Profit | -10.00K | -8,000 | -78.00K | -127.00K | -92.00K | -65.97K |
| EBITDA | -1.24M | -2.90M | -5.17M | -5.07M | -11.63M | -12.88M |
| Net Income | -1.69M | -3.29M | -5.72M | -6.74M | -15.13M | -14.45M |
Balance Sheet | ||||||
| Total Assets | 1.18M | 2.14M | 3.41M | 2.49M | 5.24M | 9.77M |
| Cash, Cash Equivalents and Short-Term Investments | 1.03M | 2.02M | 3.25M | 2.25M | 4.63M | 9.48M |
| Total Debt | 2.89M | 2.39M | 56.00K | 1.17M | 4.09M | 2.44M |
| Total Liabilities | 3.79M | 3.72M | 1.79M | 2.79M | 6.51M | 5.27M |
| Stockholders Equity | -2.61M | -1.58M | 1.61M | -294.00K | -1.27M | 4.51M |
Cash Flow | ||||||
| Free Cash Flow | -1.38M | -3.42M | -4.65M | -5.65M | -12.16M | -12.39M |
| Operating Cash Flow | -1.38M | -3.42M | -4.63M | -5.63M | -12.14M | -12.38M |
| Investing Cash Flow | 5,000 | 8,000 | -21.00K | -19.00K | -21.00K | -14.00K |
| Financing Cash Flow | 345.00K | 2.18M | 5.66M | 3.27M | 7.29M | 11.50M |
TME Pharma N.V. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTME, the sentiment is Neutral. The current price of 0.10 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.11, and above the 200-day MA of 0.09, indicating a neutral trend. The MACD of -0.00 indicates Positive momentum. The RSI at 44.40 is Neutral, neither overbought nor oversold. The STOCH value of 12.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALTME.
TME Pharma N.V. Peers Comparison
Overall Rating
FR:IPH50Neutral
FR:ALCLS47Neutral
FR:ALTME46Neutral
FR:TNG46Neutral
FR:NANO44Neutral
FR:OSE37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | EUR 101.09M | -1.77 | 152.56% | ― | -29.48% | 7.91% | |
| 47Neutral | EUR 70.88M | -0.85 | -319.92% | ― | -67.65% | -266.05% | |
| 46Neutral | EUR 10.01M | -5.75 | 80.75% | ― | ― | ― | |
| 46Neutral | EUR 192.57M | -4.14 | -29.36% | ― | 189.81% | 38.50% | |
| 44Neutral | EUR 1.32B | -23.58 | 89.71% | ― | ― | ― | |
| 37Underperform | EUR 35.79M | -0.90 | -96.73% | ― | -96.25% | -197.89% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALTME | TME Pharma N.V. | 0.10 | 0.04 | 53.73% | |
| FR:IPH | Innate Pharma S.A. | 0.91 | -0.72 | -44.14% | |
| FR:NANO | Nanobiotix SA | 25.94 | 7.74 | 42.53% | |
| FR:TNG | Transgene SA | 0.69 | -0.57 | -45.08% | |
| FR:OSE | OSE Immunotherapeutics | 1.52 | -3.83 | -71.60% | |
| FR:ALCLS | Cellectis SA | 0.98 | -3.13 | -76.13% |
TME Pharma N.V. Corporate Events
TME Pharma Details Exclusive NOX-A12 Negotiations With TMS
TME Pharma N.V. is a biotechnology company with clinical assets in brain cancer and eye diseases. Its main compounds are NOX-A12, an anti-CXCL12 L-RNA aptamer studied in glioblastoma, and NOX-E36, an L-RNA aptamer intended for ophthalmic diseases; th...
GLORIA Team Wins German University Medicine Prize for NOX-A12 Research
Researchers from six German university medical centers received the 2026 German University Medicine Prize for the GLORIA study, TME Pharma’s Phase 1/2 evaluation of NOX-A12 with radiotherapy in newly diagnosed glioblastoma patients resistant to stand...
TME Pharma Narrows Loss, Secures Funding and Partner Talks to Revive Flagship Cancer Program
TME Pharma reported its semi-annual 2026 results, showing no revenue and a sharply reduced net loss of €0.51 million amid stringent cost controls, with general and administrative and research and development expenses dropping 79% and 98%, respectivel...
TME Pharma Secures Exclusive Talks With Japan’s TMS to Advance NOX-A12 Glioblastoma Program
TME Pharma has entered into an exclusive six-month negotiation agreement with Japanese clinical-stage biotech TMS Co., which will form a dedicated subsidiary to finance and advance global development of NOX-A12 for glioblastoma. The non-binding frame...
TME Pharma Extends Debt Maturity and Secures New Bond Financing to 2028
TME Pharma has extended the maturity of all its outstanding debt from May 2027 to 30 June 2028 and secured two new bond financings, improving financial visibility until the second quarter of 2028. The company is favoring bond over equity funding to c...
TME Pharma CEO Emphasizes Cash Discipline and Strategic Partnering for Lead Cancer Asset
TME Pharma, a clinical-stage biotech group developing therapies for brain cancer and eye diseases, is centered on two key RNA aptamer assets targeting the tumor microenvironment and fibrotic pathways. The firm is advancing its NOX-A12 program in glio...
TME Pharma moves to license glioblastoma drug NOX-A12 and widens strategic focus
TME Pharma is advancing late-stage partnering plans for its flagship oncology drug NOX-A12, entering a final evaluation phase with two potential partners for a licensing deal to fund and run a phase 2 trial in glioblastoma. The asset benefits from or...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026
